bioRxiv Science⌕ Search

Biology subjects

Vielma, T. E.

Publications and source records attributed to Vielma, T. E..

3 recordsLinked to original sources

Differential activation of NF-κB and HIF-1α between alveolar-like macrophages and myeloid-derived macrophages drive inflammatory differences following Mycobacterium abscessus infection.

Pulmonary infections caused by Mycobacterium abscessus (Mab), a rapidly growing nontuberculous mycobacterium (NTM), are on the rise in patients with chronic or acquired lung disease. In contrast to immunocompetent individuals, these patient cohorts exhibit abnormal pulmonary function that result from chronic inflammation and mucus build-up. Treatment regimens rely on multi-drug cocktails yet Mabs natural recalcitrance to common antibiotics extends treatment timelines and increases the frequency of treatment failures. Thus, it is important to understand the mechanisms by which immunocompetent individuals clear Mab with relative ease while susceptible individuals do not. In the lungs, macrophages are the first immune cell Mab encounters following infection, with both resident alveolar macrophages and recruited myeloid derived macrophages playing important roles during infection control. However, the specific role of these distinct macrophage populations in regulating control and inflammatory responses during Mab remains limited due to a lack of ex vivo models that recapitulate the functions of different macrophage subsets. Here, we leverage a fetal-liver derived alveolar macrophage (FLAM) model to define early inflammatory responses occurring at the Mab-macrophage interface compared to bone-marrow derived macrophages (BMDMs). Even though both FLAMs and BMDMs similarly control intracellular Mab, the inflammatory response between these macrophage populations is significantly different. BMDMs robustly activated NF-{kappa}B transcriptional targets that include important chemokines and inflammatory cytokines like TNF, FLAMs transiently induced these genes following Mab infection. While activation of FLAMs or BMDMs with IFN{gamma} prior to Mab infection did not alter Mab intracellular dynamics, it did drive FLAMs to be more inflammatory, yet important differences remained compared to BMDMs, including the lower expression of the inducible nitric oxide synthase. This was reversed with chemical activation of HIF1. We conclude that FLAMs and BMDMs differentially respond to Mab infection due to differences in signaling networks activated following innate immune sensing, with FLAMs being more hypoinflammatory than BMDMs. More broadly our results highlight a need to better understand the initial interactions with Mab and distinct macrophage populations to define pathways that contribute to pulmonary protection or disease.

immunology↗

TGFβ primes alveolar-like macrophages to induce type I IFN following TLR2 activation

Alveolar macrophages (AMs) are key mediators of lung function and are potential targets for therapies during respiratory infections. TGF{beta} is an important regulator of AM differentiation and maintenance, but how TGF{beta} directly modulates the innate immune responses of AMs remains unclear. This shortcoming prevents effective targeting of AMs to improve lung function in health and disease. Here we leveraged an optimized ex vivo AM model system, fetal-liver derived alveolar-like macrophages (FLAMs), to dissect the role of TGF{beta} in AMs. Using transcriptional analysis, we first globally defined how TGF{beta} regulates gene expression of resting FLAMs. We found that TGF{beta} maintains the baseline metabolic state of AMs by driving lipid metabolism through oxidative phosphorylation and restricting inflammation. To better understand inflammatory regulation in FLAMs, we next directly tested how TGF{beta} alters the response to TLR2 agonists. While both TGF{beta} (+) and TGF{beta} (-) FLAMs robustly responded to TLR2 agonists, we found an unexpected activation of type I interferon (IFN) responses in FLAMs and primary AMs in a TGF{beta}-dependent manner. Surprisingly, mitochondrial antiviral signaling protein and the interferon regulator factors 3 and 7 were required for IFN production by TLR2 agonists and the IFN response was dependent on mitochondrial reactive oxygen species. Together, these data suggest that TGF{beta} modulates AM metabolic networks and innate immune signaling cascades to control inflammatory pathways in AMs.

immunology↗

GSK3α/β restrains IFNγ-inducible costimulatory molecule expression in alveolar macrophages, limiting CD4+ T cell activation

Macrophages play a crucial role in eliminating respiratory pathogens. Both pulmonary resident alveolar macrophages (AMs) and recruited macrophages contribute to detecting, responding to, and resolving infections in the lungs. Despite their distinct functions, it remains unclear how these macrophage subsets regulate their responses to infection, including how activation by the cytokine IFN{gamma} is regulated. This shortcoming prevents the development of therapeutics that effectively target distinct lung macrophage populations without exacerbating inflammation. We aimed to better understand the transcriptional regulation of resting and IFN{gamma}-activated cells using a new ex vivo model of AMs from mice, fetal liver-derived alveolar-like macrophages (FLAMs), and immortalized bone marrow-derived macrophages (iBMDMs). Our findings reveal that IFN{gamma} robustly activates both macrophage types; however, the profile of activated IFN{gamma}-stimulated genes varies greatly between these cell types. Notably, FLAMs show limited expression of costimulatory markers essential for T cell activation upon stimulation with only IFN{gamma}. To understand cell type-specific differences, we examined how the inhibition of the regulatory kinases GSK3/{beta} alters the IFN{gamma} response. GSK3/{beta} controlled distinct IFN{gamma} responses, and in AM-like cells, we found GSK3/{beta} restrained the induction of type I IFN and TNF, thus preventing the robust expression of costimulatory molecules and limiting CD4+ T cell activation. Together, these data suggest that the capacity of AMs to respond to IFN{gamma} is restricted in a GSK3/{beta}-dependent manner and that IFN{gamma} responses differ across distinct macrophage populations. These findings lay the groundwork to identify new therapeutic targets that activate protective pulmonary responses without driving deleterious inflammation.

immunology↗